Vitrolife AB (STO:VITR), an international medical device company, announced on Monday the decision by Barbro Fridén to step down as a member of the board of directors of the company, reportedly due to other future opportunities.
Fridén has been a member of the board of Vitrolife since 2010.
Vitrolife develops, produces and markets medical devices for assisted reproduction.
Headquartered in Gothenburg, Sweden, with offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, the UK and US, Vitrolife employs about 400 people and its products are sold in approximately 110 markets.
Saluda Medical secures CE certification for EVA Sensing Technology in Europe
Antin to acquire clinical trial equipment provider Emsere
Hyphens Pharma licenses Cerapro skin cream to Louis Widmer for six European markets
Profusa signs French distributor to expand Lumee Oxygen rollout in Europe
Sensiva Health names new chief operating officer
BrioHealth Solutions enrols 100th participant in BrioVAD System trial
Abbott's Amplatzer Piccolo Delivery System receives US FDA clearance and CE Mark
Amphix Bio announces initial closing of USD12.5m seed financing round
Bioretec wins FDA breakthrough status for biodegradable orthopaedic DrillPin
Amferia raises EUR3.5m to advance antimicrobial wound-care platform
BioCryst wins FDA approval for oral HAE prophylaxis in young children
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Galderma secures EU MDR certification for Sculptra, expanding use to multiple body areas
Clinical Laserthermia Systems applies for CE marking of ClearPoint Prism neuro laser system